Brief: Verve Therapeutics Announces Updates On PCSK9 Program

Verve Therapeutics

02/04/2024 12:00

April 2 (Reuters) - Verve Therapeutics Inc  VERV.O :
    * VERVE THERAPEUTICS ANNOUNCES UPDATES ON ITS PCSK9 PROGRAM
    * VERVE THERAPEUTICS - HEART-1 CLINICAL TRIAL DEMONSTRATED
LDL-C
REDUCTION OF UP TO 73% AT 0.45 MG/KG OF VERVE-101
    * VERVE THERAPEUTICS - IN LIGHT OF OBSERVED LABORATORY
ABNORMALITIES ASSOCIATED WITH VERVE-101, DECIDED TO PAUSE
ENROLLMENT IN HEART-1 TRIAL
    * VERVE THERAPEUTICS -  INITIATION OF HEART-2 CLINICAL TRIAL
OF
VERVE-102 IS EXPECTED IN 2Q 2024, CONSISTENT WITH EXISTING PCSK9
PROGRAM GUIDANCE
    * VERVE THERAPEUTICS - TO PRIORITIZE DEVELOPMENT OF
VERVE-102;
CLINICAL TRIAL APPLICATION HAS BEEN CLEARED BY THE U.K. MHRA AND
HEALTH CANADA
    * VERVE THERAPEUTICS - CASH RUNWAY REMAINS INTO LATE 2026

Source text for Eikon:  ID: 
Further company coverage:  VERV.O 

 ((Reuters.Briefs@thomsonreuters.com;))